Holen Sie sich die Stockscreener-App
1.54
4.05%
0.06
Handel nachbörslich:
1.53
-0.01
-0.65%
Schlusskurs vom Vortag:
$1.48
Offen:
$1.46
24-Stunden-Volumen:
111.67K
Relative Volume:
0.41
Marktkapitalisierung:
$40.29M
Einnahmen:
$1.79M
Nettoeinkommen (Verlust:
$-70.90M
KGV:
-0.0991
EPS:
-15.54
Netto-Cashflow:
$-34.95M
1W Leistung:
-8.88%
1M Leistung:
-27.70%
6M Leistung:
-61.69%
1J Leistung:
-21.83%
1-Tages-Spanne:
$1.46
$1.59
1-Wochen-Bereich:
$1.46
$1.6746
52-Wochen-Spanne:
$1.46
$16.94
Senti Biosciences Inc Stock (SNTI) Company Profile
Firmenname
Senti Biosciences Inc
Sektor
Branche
Telefon
(650) 239-2030
Adresse
2 CORPORATE DRIVE, FIRST FLOOR, SOUTH SAN FRANCISCO
Vergleichen Sie SNTI mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
SNTI
Senti Biosciences Inc
|
1.54 | 38.60M | 1.79M | -70.90M | -34.95M | -15.54 |
|
VRTX
Vertex Pharmaceuticals Inc
|
395.92 | 99.42B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
561.55 | 58.99B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
432.52 | 56.35B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
646.60 | 39.02B | 3.06B | 1.28B | -614.78M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
307.51 | 34.25B | 3.81B | -644.79M | -669.77M | -6.24 |
Senti Biosciences Inc Stock (SNTI) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-06-06 | Eingeleitet | Laidlaw | Buy |
| 2022-10-07 | Eingeleitet | Morgan Stanley | Equal-Weight |
Senti Biosciences Inc Aktie (SNTI) Neueste Nachrichten
Is This a Bottoming Phase for Senti Biosciences Inc.2025 Valuation Update & Risk Managed Investment Signals - beatles.ru
Senti Biosciences Reports Increased Losses Amid Strategic Moves - TipRanks
Senti Biosciences shares rise 3.38% after-hours after announcing Phase 2 dose selection for SENTI-202. - AInvest
Senti Biosciences shares fall 1.32% intraday after announcing participation in a Virtual Investor 'What This Means' segment. - AInvest
Senti Bio Participates in Virtual Investor 'What This Means” Segment Discussing The Phase 2 Dose and Schedule Selection for SENTI-202 in its Clinical Trial for Acute Myeloid Leukemia - The Manila Times
Breakthrough AML Treatment Advances: Senti Bio Reveals Phase 2 Dosing Strategy for Novel CAR-NK Cell Therapy - Stock Titan
Momentum divergence signals in Senti Biosciences Inc. chartTrading Opportunities Forecast by AI Insight - Newser
What makes Senti Biosciences Inc. stock price move sharplyReal Market Tracker with Price Action Tools - Newser
Senti Biosciences Inc. stock chart pattern explainedLow Exposure Strategy with Sector Analysis - Newser
Senti Biosciences Inc. Stock Fails to Break Resistance Traders ReactIntraday Trend Analysis for Fast Gains Released - beatles.ru
Using data tools to time your Senti Biosciences Inc. exitBreakout Monitoring with Momentum Analysis - Newser
Chardan Capital Reaffirms “Buy” Rating for Senti Biosciences (NASDAQ:SNTI) - Defense World
Senti Biosciences Inc Reports Q2 2025 Earnings: EPS at -$0.56, Revenue Misses Estimates at $0 Million - AInvest
Will Senti Biosciences Inc. announce a stock splitFree Technical Signal Summary - thegnnews.com
Senti Biosciences: A High-Risk Bet on Biotech's Future? - AInvest
Senti Biosciences completes dose finding in AML therapy trial By Investing.com - Investing.com South Africa
Senti Biosciences completes dose finding in AML therapy trial - Investing.com
Senti Bio reports Q2 results, SENTI-202 clinical development advances. - AInvest
Senti Bio Reports Second Quarter 2025 Financial Results and Confirms Next Data Milestone for Phase 1 SENTI-202 Study in Acute Myeloid Leukemia (AML) Expected Q4 2025 - The Manila Times
Senti Bio Advances AML Treatment: Phase 2 Dose Confirmed, FDA Orphan Drug Status Secured - Stock Titan
How Senti Biosciences Inc. stock performs during market volatilityTen-Year Sector Performance and Summary Analysis - Newser
Sandstorm Gold Royalties Backs Royal Gold’s Kansanshi Acquisition - The Globe and Mail
Senti Biosciences shares rise 3.49% premarket after confirming recommended Phase 2 dose for SENTI-202. - AInvest
Tools to assess Senti Biosciences Inc.’s risk profileAnnual Market Behavior and Sector Summary - Newser
Will Senti Biosciences Inc. stock recover after recent dropIn-Depth Stock Trading Volume Analysis - Newser
Is Senti Biosciences Inc. stock overhyped or has real potentialConsistent Gain Plan with AI Support - Newser
Senti Bio Determines Recommended Phase 2 Dose (RP2D) in Phase 1 Study of SENTI-202 for the Treatment of Relapsed/Refractory Hematologic Malignancies, Including Acute Myeloid Leukemia - The Manila Times
Breakthrough AML Treatment: Senti Bio's Cell Therapy Shows 67% Complete Remission at Phase 2 Dose - Stock Titan
Senti Biosciences Inc. Forms Double Bottom Pattern — Eyes on BreakoutConsistent Gain Investment Strategies Emerge - metal.it
Is Senti Biosciences Inc. stock entering bullish territoryFree Sector Based Breakout Stock Forecast - Newser
What is Senti Biosciences Inc. company’s growth strategyAchieve consistent profits with proven methods - Jammu Links News
How does Senti Biosciences Inc. generate profit in a changing economyCapitalize on market momentum for maximum gains - Jammu Links News
What are the technical indicators suggesting about Senti Biosciences Inc.Capitalize on market momentum for maximum gains - Jammu Links News
Is Senti Biosciences Inc. stock overvalued or undervaluedFree Stock Market Real-Time Monitoring - Jammu Links News
Why Senti Biosciences Inc. stock attracts strong analyst attentionFast Entry Strategy with Price Prediction - Newser
What catalysts could drive Senti Biosciences Inc. stock higher in 2025High-profit capital plays - Jammu Links News
Is Senti Biosciences Inc. a good long term investmentConsistently outstanding ROI - Jammu Links News
How does Senti Biosciences Inc. compare to its industry peersIdentify undervalued stocks poised to rally - Jammu Links News
What institutional investors are buying Senti Biosciences Inc. stockAchieve breakthrough investment performance - Jammu Links News
How many analysts rate Senti Biosciences Inc. as a “Buy”AI Powered Ideas With High Returns - Jammu Links News
Long term hold vs stop loss in Senti Biosciences Inc.Daily Technical Forecast for Quick Gains - Newser
PepGen Inc. (PEPG) Class Action Lawsuit: Levi & Korsinsky Reminds Investors of August 8, 2025 Deadline - The Globe and Mail
Is it too late to sell Senti Biosciences Inc.Free Proven Entry Plan With Low Risk Trade - Newser
Finanzdaten der Senti Biosciences Inc-Aktie (SNTI)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.67%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):